Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 9/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056853 | 0.98 | FDPS (0.48) | FDPSGGPS1CES2GPR84PPARG | |
| SCHEMBL6056832 | 0.98 | FDPS (0.48) | FDPSGGPS1CES2GPR84PPARG | |
| SCHEMBL7172854 | 0.98 | FDPS (0.48) | FDPSGGPS1CES2GPR84PPARG | |
| SCHEMBL6230681 | 0.98 | FDPS (0.45) | FDPSGGPS1AKR1B1CES2GPR84 | |
| SCHEMBL6056892 | 0.98 | FDPS (0.48) | FDPSGGPS1CES2GPR84PPARG | |
| SCHEMBL5502576 | 0.98 | FDPS (0.45) | FDPSGGPS1AKR1B1CES2GPR84 | |
| SCHEMBL1990820 | 0.98 | FDPS (0.48) | FDPSGGPS1CES2GPR84PPARG | |
| SCHEMBL1916481 | 0.98 | FDPS (0.48) | FDPSGGPS1CES2GPR84PPARG | |
| SCHEMBL6056814 | 0.98 | FDPS (0.48) | FDPSGGPS1CES2GPR84PPARG | |
| SCHEMBL6056806 | 0.98 | FDPS (0.48) | FDPSGGPS1CES2GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116399-A1 | Tumor Homing Statin Derivatives | Da Zen Theranostics, Inc. (US) | 2023-04-13 | — | — | US | claimed |
| CN-114686092-A | Photocureable coating capable of being used for metal protection and preparation method thereof | 中海油常州涂料化工研究院有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-20210008217-A1 | Tumor Homing Statin Derivatives | Da Zen Theranostics, Inc. (US) | 2021-01-14 | — | — | US | claimed |
| EP-3763389-A1 | TUMOR HOMING STATIN DERIVATIVES | Da Zen Theranostics Inc. (US) | 2021-01-13 | — | — | EP | claimed |
| CN-111068064-A | Composition comprising fatty acid or derivative thereof and dihydroxyheptanoic acid derivative | 黄泳华 | 2020-04-28 | — | — | CN | claimed |
| CN-110590638-A | Tumor-targeted statin derivative, pharmaceutical formulation and application | 德珍(中国)医疗科技有限公司 | 2019-12-20 | — | — | CN | claimed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | claimed |
| WO-2006059210-A2 | FUSED BICYCLIC PYRROLS AS HMG-COA REDUCTASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-08 | — | — | WO | claimed |
| EP-1656132-A2 | NOVEL PYRROLE-BASED HMG-COA REDUCTASE INHIBITORS | Warner-Lambert Company LLC (US) | 2006-05-17 | — | — | EP | claimed |
| EP-1625223-A2 | CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STATIN INTERMEDIATES | Diversa Corporation (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2005014539-A2 | PYRROLE-BASED HMG-COA REDUCTASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-17 | — | — | WO | claimed |
| WO-2004027075-A2 | CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STAIN INTERMEDIATES | DIVERSA CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| JP-2003518086-A | — | — | 2003-06-03 | — | — | JP | claimed |
| EP-1242365-A1 | ACYL PSEUDODIPEPTIDES WHICH CARRY A FUNCTIONALISED AUXILIARY ARM | OM Pharma (CH) | 2002-09-25 | — | — | EP | claimed |
| WO-2001046126-A1 | ACYL PSEUDODIPEPTIDES WHICH CARRY A FUNCTIONALISED AUXILIARY ARM | OM PHARMA (CH) | 2001-06-28 | — | — | WO | claimed |
| EP-0494120-A1 | HMG-CoA reductase inhibitors | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-07-08 | — | — | EP | claimed |
| EP-0480986-A1 | 6-(HYDRONAPHTYL-1-ETHYL)-4-HYDROXY-3,4,5,6-TETRAHYDRO-2H-PYRAN-2-ONES AND THE CORRESPONDING HYDROXY ACIDS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-04-22 | — | — | EP | claimed |
| US-4775681-A | Method of treating fungal infections with trans-6-[2-substitutedpyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones | WARNER-LAMBERT COMPANY (US) | 1988-10-04 | — | — | US | claimed |
| EP-0047693-B1 | PROCESS FOR THE PREPARATION OF HYDROXYARYLGLYOXYLIC ACIDS AND THEIR ALKALI SALTS, AND THEIR USE IN THE PREPARATION OF SODIUM-PARA-HYDROXYPHENYL GLYOXYLATE | SOCIETE FRANCAISE HOECHST Société anonyme dite: (FR) | 1984-02-15 | — | — | EP | claimed |
| US-4384137-A | CATALYTIC OXIDATION WITH CUPRIC IONS | SOCIETE FRANCAISE HOECHST (FR) | 1983-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116399-A1 | Tumor Homing Statin Derivatives | HMGCR, DHCR7, DHODH | FDPS 669/4885GGPS1 662/4885AKR1B1 1594/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | FDPS 3319/4885GGPS1 840/4885AKR1B1 708/4885 |
| US-20210008217-A1 | Tumor Homing Statin Derivatives | HMGCR, DHCR7, DHODH | FDPS 669/4885GGPS1 662/4885AKR1B1 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.